News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
282,502 Results
Type
Article (14974)
Company Profile (299)
Press Release (267223)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79980)
Career Advice (162)
Deals (13353)
Drug Delivery (39)
Drug Development (50870)
Employer Resources (31)
FDA (5895)
Job Trends (5216)
News (145475)
Policy (10139)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (921)
Accelerated approval (20)
Adcomms (14)
Allergies (81)
Alliances (21808)
ALS (124)
Alzheimer's disease (1030)
Antibody-drug conjugate (ADC) (241)
Approvals (6091)
Artificial intelligence (258)
Autoimmune disease (110)
Automation (9)
Bankruptcy (105)
Best Places to Work (4609)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (345)
Cancer (3154)
Cardiovascular disease (237)
Career advice (147)
Career pathing (7)
CAR-T (217)
CDC (5)
Cell therapy (563)
Cervical cancer (14)
Clinical research (43801)
Collaboration (1153)
Company closure (2)
Compensation (592)
Complete response letters (39)
COVID-19 (1100)
CRISPR (86)
C-suite (550)
Cystic fibrosis (112)
Data (4331)
Denatured (15)
Depression (92)
Diabetes (254)
Diagnostics (1407)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (188)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (220)
Earnings (31736)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51836)
Executive appointments (621)
FDA (7654)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (10)
Frontotemporal dementia (22)
Funding (982)
Gene editing (182)
Generative AI (21)
Gene therapy (487)
GLP-1 (504)
Government (1160)
Grass and pollen (3)
Guidances (166)
Healthcare (6636)
HIV (18)
Huntington's disease (44)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (39)
Indications (66)
Infectious disease (1204)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7357)
IRA (12)
Job creations (868)
Job search strategy (129)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1402)
Liver cancer (41)
Longevity (11)
Lung cancer (439)
Lymphoma (248)
Machine learning (24)
Management (7)
Manufacturing (377)
MASH (130)
Medical device (2665)
Medtech (2674)
Mergers & acquisitions (6619)
Metabolic disorders (724)
Multiple sclerosis (102)
NASH (13)
Neurodegenerative disease (232)
Neuropsychiatric disorders (70)
Neuroscience (1952)
Neurotech (1)
NextGen: Class of 2026 (2037)
Non-profit (869)
Now hiring (30)
Obesity (329)
Opinion (125)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (327)
Peanut (43)
People (26663)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15516)
Phase 2 (20353)
Phase 3 (12873)
Pipeline (3252)
Policy (91)
Postmarket research (854)
Preclinical (6553)
Press Release (30)
Prostate cancer (146)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (649)
Real estate (1447)
Recruiting (12)
Regulatory (9967)
Reports (19)
Research institute (973)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (182)
Series B (135)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2005)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (333)
Venture capital (70)
Weight loss (173)
Women's health (25)
Worklife (2)
Date
Today (6)
Last 7 days (345)
Last 30 days (1305)
Last 365 days (17889)
2026 (1657)
2025 (18154)
2024 (20629)
2023 (22539)
2022 (26928)
2021 (27886)
2020 (23442)
2019 (16283)
2018 (11781)
2017 (13791)
2016 (11889)
2015 (14407)
2014 (10413)
2013 (7501)
2012 (7550)
2011 (7633)
2010 (7442)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18343)
Australia (3111)
California (7085)
Canada (1854)
China (779)
Colorado (277)
Connecticut (254)
Delaware (236)
Europe (39264)
Florida (902)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (35)
Indiana (160)
Iowa (8)
Japan (224)
Kansas (80)
Kentucky (10)
Louisiana (7)
Maine (11)
Maryland (742)
Massachusetts (5614)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1667)
New Mexico (13)
New York (1761)
North Carolina (825)
North Dakota (6)
Northern California (3481)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1276)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2808)
Tennessee (40)
Texas (906)
United States (23403)
Utah (97)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (45)
282,502 Results for "exonics therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Duchenne muscular dystrophy
Dyne’s Exon Skipper Delivers ‘Best Ever’ Functional Outcomes in Early DMD Study
Dyne’s exon-skipping therapy zeleciment rostudirsen resulted in an approximately sevenfold increase in dystrophin levels at six months and elicited functional improvements that are the “best ever” for this treatment class, Stifel analysts said.
December 8, 2025
·
2 min read
·
Tristan Manalac
Duchenne muscular dystrophy
Sarepta’s DMD Exon-Skippers Fail Confirmatory Study, Stock Craters
Sarepta nevertheless plans to push for full FDA approval of Vyondys 53 and Amondys 45 based on what it said are “encouraging trends” in efficacy.
November 4, 2025
·
2 min read
·
Tristan Manalac
Press Releases
ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
December 5, 2025
·
6 min read
Press Releases
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025
December 2, 2025
·
2 min read
Duchenne muscular dystrophy
Dyne’s Duchenne Exon Skipping Oligomer Shows ‘Differentiated’ Clinical Effect
Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys 51 in a patient population amenable to exon 51 skipping.
March 17, 2025
·
2 min read
·
Tristan Manalac
Press Releases
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025
December 4, 2025
·
2 min read
Press Releases
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
November 21, 2025
·
9 min read
Business
Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases
Ascidian Therapeutics today announced a research collaboration and licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery and development of RNA exon editing therapeutics targeting neurological diseases.
June 18, 2024
·
3 min read
Press Releases
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
December 8, 2025
·
8 min read
Press Releases
Exonate plans ‘CLEAR-DE’ Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disease
July 29, 2025
·
2 min read
1 of 28,251
Next
